We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Stages of Pulmonary Embolism

By HospiMedica staff writers
Posted on 02 Nov 2005
A new rule classifies patients who have pulmonary embolism into five disease stages that reveal an increasing risk of death or other adverse outcome.

Investigators studied data from 15, 531 discharged patients hospitalized for pulmonary embolism at hospitals in Pennsylvania (USA). More...
They divided the patients into two groups: one to develop the rule and the other to verify their conclusions.

A pulmonary embolism involves a clot that travels through the bloodstream and suddenly blocks an artery of the lung. The most common type begins in either a leg or pelvic vein. Once a clot breaks loose, it tends to travel to the lung. The researchers looked at 11 patient factors independently associated with 30-day patient mortality from pulmonary embolism. These were two demographic factors (age and male sex); three illnesses (cancer, heart failure, and chronic lung disease); and six clinical findings on measurements of pulse, systolic blood pressure, respiratory rate, temperature, altered mental state (disorientation, lethargy, stupor), and arterial oxygen saturation level. Each of these parameters was assigned a numerical score to quantify it with the potential for death.

According to the authors, the rule identifies patients who are at either low or high risk of fatal and nonfatal medical outcomes associated with pulmonary embolism. For example, the 30-day mortality rate for a class I score was 1.6% or less. For class II, it was 3.5%. At class V, it ranged from 10-24.5%. Through outpatient management or early hospital discharge of patients identified as very low risk in class I or low-risk in class II, the rule could save costs without adding risk to the patient, once its usefulness has been confirmed in a prospective study.

The study was led by Drahomir Aujesky of the Centre Hospitalier Universitaire Vadois in Lausanne (Switzerland). The findings were published in the second issue for October 2005 of the American Journal of Respiratory and Critical Care Medicine.


Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Gold Member
Electrode Solution and Skin Prep
Signaspray
Autoclave
Advance
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.